ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis

Company Overview

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $17.06 to $17.06
• 50-Day Range: $17.06 to $17.06
• 52-Week Range: $2.13 to $18.00
• Volume: 39 shs
• Average Volume: 11,851 shs
• Market Capitalization: $834.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CXRXF Stock Analysis - Frequently Asked Questions

How have CXRXF shares performed this year?

ADVANZ PHARMA's stock was trading at $17.06 on January 1st, 2025. Since then, CXRXF stock has increased by 0.0% and is now trading at $17.06.
View the best growth stocks for 2025 here.

How do I buy shares of ADVANZ PHARMA?

Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CXRXF
• CIK: N/A
• Web: www.advanzpharma.com
• Phone: 44-20-8588-9100
• Fax: N/A
• Employees: 429
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-74,860,000.00
• Net Margins: -15.31%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -4.38%

Debt

• Debt-to-Equity Ratio: 257.04
• Current Ratio: 2.39
• Quick Ratio: 1.61

Sales & Book Value

• Annual Sales: $525.58 million
• Price / Sales: 1.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.16 per share
• Price / Book: 106.63

Miscellaneous

• Outstanding Shares: 48,913,000
• Free Float: N/A
• Market Cap: $834.46 million
• Optionable: Not Optionable
• Beta: N/A